Voyageur Pharmaceuticals Ltd. Stock OTC Markets
Stocks
VYYR.F
CA92918C1014
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0140 USD | 0.00% |
|
0.00% | -89.24% |
| Market Cap | 20.37M 14.55M 12.62M 11.64M 10.9M 1.39B 20.8M 139M 53.74M 671M 54.61M 53.43M 2.33B | P/E Ratio 2024 |
-5.24x | P/E Ratio 2025 | -7.5x |
|---|---|---|---|---|---|
| Enterprise Value | 20.14M 14.38M 12.48M 11.5M 10.78M 1.38B 20.56M 137M 53.13M 664M 53.99M 52.82M 2.31B | EV / Sales 2024 |
-
| EV / Sales 2025 | 2,423,581,172x |
| Free-Float |
91.6% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 month | -81.33% | ||
| 3 months | -87.50% | ||
| 6 months | -86.00% | ||
| Current year | -89.24% |
| 1 month | 0.01 | 0.08 | |
| Current year | 0.01 | 0.13 | |
| 1 year | 0 | 0.24 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.25 | |
| 10 years | 0 | 0.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brent Willis
CEO | Chief Executive Officer | - | 01/07/2019 |
| Director of Finance/CFO | - | 17/08/2022 | |
Iryna Saranchova
CTO | Chief Tech/Sci/R&D Officer | - | 17/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Brent Willis
BRD | Director/Board Member | - | 06/12/2017 |
Brad Willis
BRD | Director/Board Member | - | 01/07/2019 |
Eric Pommer
CHM | Chairman | - | 30/04/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | - | - | 16.25M | ||
| +2.16% | +3.17% | +43.57% | +160.28% | 1,013B | ||
| -0.07% | +4.45% | +53.50% | +48.95% | 574B | ||
| -0.08% | -0.08% | +17.37% | +62.66% | 397B | ||
| +0.77% | +0.77% | +21.19% | +15.95% | 324B | ||
| +0.85% | +0.18% | +24.50% | +15.93% | 280B | ||
| +2.10% | +4.92% | +25.30% | +34.79% | 273B | ||
| -0.19% | -0.46% | -45.32% | -48.23% | 194B | ||
| +4.84% | +2.45% | +21.33% | +61.85% | 182B | ||
| +3.61% | -2.56% | +15.16% | +61.12% | 151B | ||
| Average | +1.40% | +2.19% | +19.62% | +45.92% | 376.52B | |
| Weighted average by Cap. | +1.35% | +2.65% | +29.45% | +72.50% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.39 0.03 0.03 1.34 |
| Net income | -1.71M -1.22M -1.06M -975K -914K -117M -1.74M -11.63M -4.5M -56.27M -4.58M -4.48M -196M | -3.53M -2.52M -2.19M -2.02M -1.89M -242M -3.61M -24.07M -9.32M -116M -9.47M -9.27M -405M |
| Net Debt | -113K -80.43K -69.79K -64.33K -60.28K -7.7M -115K -767K -297K -3.71M -302K -295K -12.91M | -231K -165K -143K -132K -123K -15.76M -235K -1.57M -608K -7.6M -618K -605K -26.42M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VM Stock
- VYYR.F Stock
Select your edition
All financial news and data tailored to specific country editions
















